Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bionomics Limited BNOX
$2.59
+$0.25 (9.75%)
На 18:05, 12 мая 2023
+131.66%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
19118211.00000000
-
week52high
10.90
-
week52low
1.80
-
Revenue
263634
-
P/E TTM
-1
-
Beta
2.28244200
-
EPS
-2.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 дек 2022 г. в 00:00
Описание компании
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Bionomics Limited to Participate in Upcoming November Investor Conferences
GlobeNewsWire
02 ноя 2022 г. в 06:00
ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in November:
Bionomics to Participate in Upcoming September Investor Conferences
GlobeNewsWire
31 авг 2022 г. в 06:00
ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in September:
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
InvestorPlace
07 июн 2022 г. в 13:00
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.
Bionomics Limited to Participate in Upcoming Investor Conferences
GlobeNewsWire
16 мая 2022 г. в 06:00
ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences: